Differential Effects of Vasopressin and Oxytocin on Attention Control

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-19

Study Completion Date

2021-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim of the present study is to investigate whether intranasal vasopressin (20IU) and oxytocin (24IU) have differential effects on attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Differential Effects of Oral and Intranasal Oxytocin on Attention Control

NCT04815395

Healthy

COMPLETED NA

Oral Oxytocin's Effects on Attention Control

NCT04493515

Healthy

UNKNOWN NA

The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )

NCT07140237

Healthy Adult Male

RECRUITING EARLY_PHASE1

The Effect of Oral Oxytocin and Atosiban on Social Attention

NCT07093060

Healhty

RECRUITING EARLY_PHASE1

Effects of Intranasal Oxytocin on Emotion Regulation

NCT03055546

Healthy

UNKNOWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Previous studies have demonstrated intranasal vasopressin and oxytocin's divergent effects on social behavior and emotion processing such as empathy and negative emotion processing, however, it remains unclear whether vasopressin and oxytocin treatment would have differential effects on attention processing to social stimuli. Based on the previous registered studies (ClinicalTrials.gov ID: NCT04493554 and NCT03486925) from our group using a validated emotional anti-saccade task with social stimuli (emotional faces) and non-social stimuli (oval shape) have separately explored intranasal vasopressin and oxytocin's modulatory effects on attention processing, the present study aims to conduct a secondary analysis of the previously acquired data to directly compare vasopressin and oxytocin's effects on attention control to social emotional stimuli. To this end data from subjects who underwent intranasal oxytocin administration (n = 33; NCT03486925) will be compared with data from subjects who underwent intranasal vasopressin or placebo administration (n = 39, or 45 respectively; NCT04493554). To further control for non-treatment related factors the intranasal placebo groups from the previous studies (ClinicalTrials.gov ID: NCT04493554 and NCT03486925) will be compared with respect to primary and secondary outcome measures of the trial, in particular general and emotion-specific effects on attentional control.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Between-subject randomized placebo-controlled double-blind pharmacological eye-tracking design

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vasopressin

Vasopressin (20IU) intranasally

Group Type EXPERIMENTAL

Vasopressin

Intervention Type DRUG

Administration of vasopressin (20IU) intranasally

Oxytocin

Oxytocin (24IU) intranasally

Group Type EXPERIMENTAL

Oxytocin

Intervention Type DRUG

Administration of oxytocin (24IU) intranasally

Placebo

Placebo intranasally

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administration of placebo intranasally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vasopressin

Administration of vasopressin (20IU) intranasally

Intervention Type DRUG

Oxytocin

Administration of oxytocin (24IU) intranasally

Intervention Type DRUG

Placebo

Administration of placebo intranasally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male, healthy participants
* Non smokers

Exclusion Criteria

* Previous or current medical, psychiatric, neurological disorder
* Regular medication
* Use of any psychoactive substances in the 24 hours before experiment

Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes